FindTrial
Sign In

To assess blood markers to predict terminal disease in patients suffering from advanced cancers.

Prognostic haematological biomarkers for predicting terminal illness and end of life in patients with advanced cancers receiving palliative care in a tertiary care centre- a prospective cohort study. a PREDICTIVE BIOCARE study [PREDICTIVE BIOmarker in advanced CAncer patients Receiving End-of-life care.]

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/11/097425
Enrollment
225
Registered
2025-11-13
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil Intervention4: Nil: Nil

Sponsors

Rakesh Garg
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with advanced cancer, Palliative Prognostic Index of more than four, knows and understands Hindi and English, able to consent to participation in the study.

Exclusion criteria

Exclusion criteria: 1. Death due to other causes not related to cancer, for example, accidental deaths, deaths in natural calamities. 2. Pre-existing diseases not related to cancer affecting the studied biomarkers, like congenital liver disorders (Dubin-Johnson syndrome, Rotor syndrome), congenital renal disorders, and other congenital diseases like cystic fibrosis, etc. 3. Patients with known haematological disorders, such as sickle cell anaemia and thalassemia, who are already presenting with anaemia. 4. Congenital immunodeficient states like SCID (Severe Combined Immunodeficiency Disorder), CVID (Common Variable Immunodeficiency Disorder), etc.

Design outcomes

Primary

MeasureTime frame
To identify prognostic biomarkers of haemoglobin, total leukocyte count, Neutrophil Lymphocyte Ratio (NLR), Platelet Lymphocyte Ratio (PLR), CRP (C- Reactive Protein)/Albumin for predicting terminal illness and end of life in adult patients with advanced cancers receiving palliative care Timepoint: 2 weeks, 4 weeks, 6 weeks—

Secondary

MeasureTime frame
Secondary objective: A. To identify prognostic markers among 1. Renal function test: Serum Urea/ Serum Creatinine 2. Liver function test: Bilirubin / Aspartate Aminotransferase / Alanine Aminotransferase / Alkaline phosphatase 3. Electrolytes: Sodium (Na) / Potassium (K) / Calcium (Ca) / Phosphate / Chloride (Cl-) / Magnesium (Mg) / Bicarbonate 4. Lactate Dehydrogenase (LDH) 5. D-dimer in adult patients with advanced cancers receiving palliative care B. Change in trends of haematological biomarkers at baseline and 2 weeks in adult patients with advanced cancers receiving palliative care Timepoint: 2 weeks, 4 weeks, 6 weeks—

Countries

India

Contacts

Public ContactDr Rakesh Garg

Department of Onco-Anaesthesia and Palliative Medicine, AIIMS, New Delhi.

drrgarg@hotmail.com9810394950

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026